Cutter & CO Brokerage Inc. Raises Stock Holdings in Danaher Co. (NYSE:DHR)

Cutter & CO Brokerage Inc. raised its position in Danaher Co. (NYSE:DHR) by 5.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,151 shares of the conglomerate’s stock after buying an additional 116 shares during the quarter. Cutter & CO Brokerage Inc.’s holdings in Danaher were worth $598,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DHR. LVW Advisors LLC purchased a new stake in Danaher in the first quarter valued at approximately $235,000. Claro Advisors LLC acquired a new position in shares of Danaher in the first quarter valued at approximately $255,000. Capital Advisors Ltd. LLC increased its holdings in shares of Danaher by 2.4% in the first quarter. Capital Advisors Ltd. LLC now owns 1,888 shares of the conglomerate’s stock valued at $471,000 after purchasing an additional 44 shares during the period. Azzad Asset Management Inc. ADV increased its holdings in shares of Danaher by 0.5% in the first quarter. Azzad Asset Management Inc. ADV now owns 11,586 shares of the conglomerate’s stock valued at $2,893,000 after purchasing an additional 62 shares during the period. Finally, Valeo Financial Advisors LLC increased its holdings in shares of Danaher by 9.9% in the first quarter. Valeo Financial Advisors LLC now owns 12,812 shares of the conglomerate’s stock valued at $3,199,000 after purchasing an additional 1,152 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 0.7 %

Shares of DHR stock traded down $1.71 during trading hours on Tuesday, reaching $242.41. The company had a trading volume of 380,662 shares, compared to its average volume of 2,728,358. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a market capitalization of $179.55 billion, a P/E ratio of 41.38, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The stock’s fifty day simple moving average is $268.98 and its 200 day simple moving average is $260.53.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the firm earned $2.02 earnings per share. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. As a group, sell-side analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Insider Activity

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,059 shares of company stock worth $8,400,897. 11.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

DHR has been the topic of several research reports. TD Cowen upped their target price on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Bank of America upped their price objective on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. KeyCorp upped their price objective on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Stephens reiterated an “overweight” rating and set a $315.00 target price on shares of Danaher in a research report on Wednesday, October 23rd. Finally, Wells Fargo & Company initiated coverage on Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price on the stock. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $287.28.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.